T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1/2
21
about 3.6 years
18+
2 sites in CA, TX
About this study
This trial is testing a new treatment called EB103 for adults with relapsed or refractory B-cell non-Hodgkin's lymphoma. The goal is to determine how safe this treatment is and what dose works best.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive EB103
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Incidence rates of Treatment-Emergent Adverse Events of EB103.
Secondary: To assess the Disease Control Rate of EB103 in our study subject population., To assess the Duration of Response of EB103 in our study subject population., To assess the Event-Free Survival rate of EB103 in our study subject population., To assess the Overall Response Rate of EB103 in our study subject population., To assess the Overall Survival rate of EB103 in our study subject population., To assess the Progression-Free Survival rate of EB103 in our study subject population., To characterize the pharmacokinetic (PK) profile of EB103 by measuring the partial area under the curve (pAUC)., To characterize the pharmacokinetic (PK) profile of EB103 by measuring the peak exposure (Cmax).
Oncology